NEW YORK (GenomeWeb News) – Genzyme has licensed the diagnostic testing rights to two proteins from the Moffitt Cancer Center that it plans to develop into tests that could help predict patients’ response to non-small cell lung cancer treatments, the company said today.
Tampa, Fla.-based Moffitt, designated a Comprehensive Cancer Center by the National Cancer Institute, has found that the proteins RRM1 and ERCC1 may help to predict the effectiveness of NSCLC treatments, because the expression levels of the proteins correlated to responses to two common drugs.
Genzyme said it will develop and market a diagnostic test to measure the expression level of these proteins in NSCLC patients in order to help direct doctors trying to make first-line treatment decisions. Cambridge, Mass.-based Genzyme will provide Moffitt with milestone payments and royalties from the sale of any licensed products or services stemming from the research.
Genzyme’s national medical director, Bruce Horten, said the first-line treatment step for NSCLC is “a key decision point in the management of patients for whom getting the right drug as quickly as possible is critical.”